Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Stock Information for Volato Group Inc. Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Volato Group Inc. Class A

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology
Agenus Announces Virtual Annual Shareholders Meeting
Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US
Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer
Agenus Reports Q1 2025 Financial Results and Key Business Updates
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.